Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 51Leukemia 26Myelodysplastic Syndromes 10Leukemia, Myelomonocytic, Acute 10Leukemia, Monocytic, Acute 9Leukemia, Megakaryoblastic, Acute 8Leukemia, Erythroblastic, Acute 8Congenital Abnormalities 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Blast Crisis 5Anemia, Refractory, with Excess of Blasts 5Recurrence 4Leukemia, Promyelocytic, Acute 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Eosinophilic, Acute 4Liver Neoplasms 3Leukemia, Myeloid, Chronic-Phase 3Leukemia, Myeloid, Accelerated Phase 3Leukemia, Biphenotypic, Acute 3Leukemia, Basophilic, Acute 3Carcinoma, Hepatocellular 3Myeloproliferative Disorders 2Lung Neoplasms 2Graft vs Host Disease 2Thrombocythemia, Essential 1Sarcoma, Myeloid 1Primary Myelofibrosis 1Polycythemia Vera 1Neutropenia 1

Interventions

Cytarabine 3Cyclophosphamide 3thymoglobulin 2fludarabine phosphate 2fludarabine 2Thiotepa 2Tacrolimus 2Rituximab 2Melphalan 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2vosaroxin 1plerixafor 1devimistat 1blinatumomab 1aldesleukin 1Transplantation 1Sirolimus 1Razoxane 1Mycophenolic Acid 1Metformin 1Mesna 1Interleukin-2 1Idarubicin 1Gemtuzumab 1Dexrazoxane 1Clofarabine 1Cladribine 1Busulfan 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Sarcoma, Myeloid × Idarubicin × Clear all
NCT03589729 2026-05-22

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

M.D. Anderson Cancer Center

Phase 2 Recruiting
100 enrolled
MyeloidOther hematologic neoplasmSarcoma

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡